Motion Sickness Questions & Answers

1. Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ. 2011. 343:d7430. [QxMD MEDLINE Link].

2. Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med. 2006 Dec. 77(12):1213-23. [QxMD MEDLINE Link].

3. Golding JF. Motion sickness susceptibility. Auton Neurosci. 2006 Oct 30. 129(1-2):67-76. [QxMD MEDLINE Link].

4. Nachum Z, Shupak A, Gordon CR. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2006. 45(6):543-66. [QxMD MEDLINE Link].

5. Dobie TG, May JG. Cognitive-behavioral management of motion sickness. Aviat Space Environ Med. 1994 Oct. 65(10 Pt 2):C1-2. [QxMD MEDLINE Link].

6. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988 May. 59(5):399-406. [QxMD MEDLINE Link].

7. Haward BM, Lewis CH, Griffin MJ. Motions and crew responses on an offshore oil production and storage vessel. Appl Ergon. 2009 Sep. 40(5):904-14. [QxMD MEDLINE Link].

8. Chan G, Moochhala SM, Zhao B, Wl Y, Wong J. A comparison of motion sickness prevalence between seafarers and non-seafarers onboard naval platforms. Int Marit Health. 2006. 57(1-4):56-65. [QxMD MEDLINE Link].

9. Klosterhalfen S, Kellermann S, Pan F, Stockhorst U, Hall G, Enck P. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med. 2005 Nov. 76(11):1051-7. [QxMD MEDLINE Link].

10. Brainard A, Gresham C. Prevention and treatment of motion sickness. Am Fam Physician. 2014 Jul 1. 90 (1):41-6. [QxMD MEDLINE Link].

11. Holtmann S, Clarke AH, Scherer H, Höhn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol. 1989 Sep-Oct. 108(3-4):168-74. [QxMD MEDLINE Link].

12. Keshavarz B, Stelzmann D, Paillard A, Hecht H. Visually induced motion sickness can be alleviated by pleasant odors. Exp Brain Res. 2015 May. 233 (5):1353-64. [QxMD MEDLINE Link].

13. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol. 1988 Jan-Feb. 105(1-2):45-9. [QxMD MEDLINE Link].

14. Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology. 1991. 42(2):111-20. [QxMD MEDLINE Link].

15. White B. Ginger: an overview. Am Fam Physician. 2007 Jun 1. 75(11):1689-91. [QxMD MEDLINE Link].

16. Ozgoli G, Goli M, Simbar M. Effects of ginger capsules on pregnancy, nausea, and vomiting. J Altern Complement Med. 2009 Mar. 15(3):243-6. [QxMD MEDLINE Link].

17. Yen Pik Sang FD, Golding JF, Gresty MA. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviat Space Environ Med. 2003 Sep. 74(9):998-1002. [QxMD MEDLINE Link].

18. Dobie TG, May JG. Cognitive-behavioral management of motion sickness. Aviat Space Environ Med. 1994 Oct. 65(10 Pt 2):C1-2. [QxMD MEDLINE Link].

19. Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med. 2004 Mar. 75(3):227-34. [QxMD MEDLINE Link].

20. Stern RM, Hu S, LeBlanc R, Koch KL. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med. 1993 Sep. 64(9 Pt 1):827-30. [QxMD MEDLINE Link].

21. Dobie T, McBride D, Dobie T Jr, May J. The effects of age and sex on susceptibility to motion sickness. Aviat Space Environ Med. 2001 Jan. 72(1):13-20. [QxMD MEDLINE Link].

22. Golding JF, Gresty MA. Motion sickness. Curr Opin Neurol. 2005 Feb. 18(1):29-34. [QxMD MEDLINE Link].

23. Lawson BD, Mead AM. The sopite syndrome revisited: drowsiness and mood changes during real or apparent motion. Acta Astronaut. 1998 Aug-Sep. 43(3-6):181-92. [QxMD MEDLINE Link].

24. Cha YH. Mal de debarquement. Semin Neurol. 2009 Nov. 29(5):520-7. [QxMD MEDLINE Link].

25. Wood CD, Manno JE, Wood MJ, Manno BR, Mims ME. Comparison of efficacy of ginger with various antimotion sickness drugs. Clin Res Pr Drug Regul Aff. 1988. 6(2):129-36. [QxMD MEDLINE Link].

26. Estrada A, LeDuc PA, Curry IP, Phelps SE, Fuller DR. Airsickness prevention in helicopter passengers. Aviat Space Environ Med. 2007 Apr. 78(4):408-13. [QxMD MEDLINE Link].

27. Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011. (6):CD002851. [QxMD MEDLINE Link].

28. Nachum Z, Shupak A, Gordon CR. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2006. 45(6):543-66. [QxMD MEDLINE Link].

29. Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther. 2001 Jan. 296(1):121-3. [QxMD MEDLINE Link].

30. Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med. 2010 Apr. 81(4):405-12. [QxMD MEDLINE Link].

31. Doweck I, Gordon CR, Spitzer O, Melamed Y, Shupak A. Effect of cinnarizine in the prevention of seasickness. Aviat Space Environ Med. 1994 Jul. 65(7):606-9. [QxMD MEDLINE Link].

32. Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol. 2001 Sep. 15(3):167-72. [QxMD MEDLINE Link].

33. Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res. 2007. 17(5-6):301-11. [QxMD MEDLINE Link].

34. Cox DJ, Singh H, Cox DM. Effectiveness of acupressure and acustimulation in minimizing driving simulation adaptation syndrome. Mil Med. 2011 Dec. 176(12):1440-3. [QxMD MEDLINE Link].

35. Wood CD, Manno JE, Wood MJ, Manno BR, Mims ME. Comparison of efficacy of ginger with various antimotion sickness drugs. Clin Res Pr Drug Regul Aff. 1988. 6(2):129-36. [QxMD MEDLINE Link].

36. Lee A, Fan LT. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2009. (2):CD003281. [QxMD MEDLINE Link].

37. Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med. 1995 Jul. 66(7):631-4. [QxMD MEDLINE Link].

38. Bertolucci LE, DiDario B. Efficacy of a portable acustimulation device in controlling seasickness. Aviat Space Environ Med. 1995 Dec. 66(12):1155-8. [QxMD MEDLINE Link].

39. Gil A, Nachum Z, Tal D, Shupak A. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol. 2012 Jan. 35(1):37-9. [QxMD MEDLINE Link].

40. Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009 Sep. 29(9):1082-8. [QxMD MEDLINE Link].

41. Hershkovitz D, Asna N, Shupak A, Kaminski G, Bar R, Tal D. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med. 2009 Jul. 80(7):643-6. [QxMD MEDLINE Link].

42. McClure JA, Lycett P, Baskerville JC. Diazepam as an anti-motion sickness drug. J Otolaryngol. 1982 Aug. 11(4):253-9. [QxMD MEDLINE Link].

43. Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med. 2007 Jul. 78(7):686-92. [QxMD MEDLINE Link].

44. Weichenthal L, Soliz T. The incidence and treatment of prehospital motion sickness. Prehosp Emerg Care. 2003 Oct-Dec. 7(4):474-6. [QxMD MEDLINE Link].

45. Wright MS, Bose CL, Stiles AD. The incidence and effects of motion sickness among medical attendants during transport. J Emerg Med. 1995 Jan-Feb. 13(1):15-20. [QxMD MEDLINE Link].

46. Golding JF, Gresty MA. Pathophysiology and treatment of motion sickness. Curr Opin Neurol. 2015 Feb. 28 (1):83-8. [QxMD MEDLINE Link].

Andrew Brainard, MD, MPH Consultant Emergency Medical Physician, Director of Emergency Medical Education, Middlemore Hospital, New Zealand

Andrew Brainard, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Wilderness Medical Society

Disclosure: Nothing to disclose.

Chip Gresham, MD, FACEM † Emergency Medicine Physician, Medical Toxicologist, and Intensive Care Consultant, Department of Emergency Medicine, Clinical Director of Medication Safety, Middlemore Hospital; Consultant Toxicologist, National Poisons Centre; Director, Auckland Regional Toxicology Service; Senior Lecturer, Auckland University Medical School, New Zealand

Chip Gresham, MD, FACEM is a member of the following medical societies: American College of Emergency Physicians, American College of Medical Toxicology, Australasian College for Emergency Medicine, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Bioserenity, Ceribell, Eisai, Jazz, LivaNova, Neurelis, Neuropace, SK life science, Sunovion, Takeda, UCB<br/>Serve(d) as a speaker or a member of a speakers bureau for: Aquestive, Bioserenity, Eisai, Jazz, LivaNova, Neurelis, SK life science, Stratus, Sunovion, UCB<br/>Received research grant from: Cerevel Therapeutics, Ovid Therapeutics, Neuropace, Greenwich Jazz, SK Life Science, Xenon Pharmaceuticals, UCB, Marinus, Neuroelectrics Corporation, Longboard, Janssen, Equilibre Biopharmaceuticals.

• Print this section
• Print the entire contents of
• Print the entire contents of article